Accuray | Jotup

Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024

Retrieved on:

Wednesday, April 17, 2024

MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.

Key Points:

MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.
ET on May 1, 2024.
A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com .
A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2024.

New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

Retrieved on:

Tuesday, March 26, 2024

Radiation, Prostate cancer, Disease, Incidence, Patient, Rectum, RSS, Prostate, Motion, SBRT, Quality of life, Cyberknife, MBA, Neoplasm, Accuray, Movement, Health, Medical imaging

MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams.

Key Points:

"An extensive number of peer-reviewed scientific manuscripts have been published reporting on CyberKnife prostate SBRT efficacy and tolerability.
The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT.
Provide a viable option with "a low incidence of short-term genitourinary (GU) and gastrointestinal (GI) toxicities" for reirradiation of locally recurrent prostate cancer2.
For example, if the prostate moves during treatment the CyberKnife® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time.

Accuray Incorporated to Speak at 36th Annual Roth Conference

Retrieved on:

Monday, March 4, 2024

EST, Fireside chats, Accuray, Conference, PST

MADISON, Wis., March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 36th Annual Roth Conference. The management team is scheduled to take part in a fireside chat on Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST.

Key Points:

Company to Take Part in Fireside Chat Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST
MADISON, Wis., March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY ) announced today its participation in the 36th Annual Roth Conference.
The management team is scheduled to take part in a fireside chat on Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST.
A live webcast of the fireside chat can be accessed on the Accuray website at investors.accuray.com .
The 36th Annual Roth Conference will connect institutional investors with companies from diverse industry sectors.

Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Retrieved on:

Tuesday, February 27, 2024

EST, Fireside chats, Accuray, Conference, Medtech, PST

MADISON, Wis., Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024. The management team is scheduled to participate in a fireside chat on Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST.

Key Points:

Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST
MADISON, Wis., Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.
The management team is scheduled to participate in a fireside chat on Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST.
A live webcast of the fireside chat can be accessed on the Accuray website at investors.accuray.com .
The Oppenheimer Conference will connect institutional investors to a wide variety of public and private healthcare companies spanning all major sectors of the healthcare industry.

The Froedtert & Medical College of Wisconsin health network selects RayStation

Retrieved on:

Thursday, January 18, 2024

Patient, Radiation therapy, Medical college, Health, Proton therapy, Froedtert Hospital, RaySearch Laboratories, Cancer, MCW, LET, Accuray

STOCKHOLM, Jan. 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.

Key Points:

STOCKHOLM, Jan. 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.
The Froedtert & MCW health network has purchased RayStation for photon treatments on its Elekta linear accellerators and the Accuray Radixact® treatment delivery system, as well as hyperscanning proton licenses for the health network's upcoming Mevion S250i proton therapy system.
The Froedtert & MCW health network offers a nationally and internationally recognized premier cancer program with six cancer centers anchored by the only academic medical center in eastern Wisconsin.
The Clinical Cancer Center at the health network's Froedtert Hospital campus anticipates being the first center in Wisconsin to offer proton therapy.

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024

Retrieved on:

Tuesday, January 16, 2024

Accuray

MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.

Key Points:

MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.
ET on January 31, 2024.
A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com .
A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the third quarter of fiscal 2024.

Oregon Health & Science University (OHSU) to utilize RayStation technology for radiation therapy planning

Retrieved on:

Tuesday, October 31, 2023

Cancer, Medicine, Patient, RaySearch Laboratories, Health, OHSU, Research, Medical device, Accuray, Physics, Q3

The center intends to implement adaptive therapy to acquire daily patient images and perform treatment adaptations such that the patient's treatment is optimized.

Key Points:

The center intends to implement adaptive therapy to acquire daily patient images and perform treatment adaptations such that the patient's treatment is optimized.
OHSU and RaySearch consider this approach to precision medicine to be the future of radiation therapy.
Dr. John Bayouth, Vice Chair, Director of Physics and Chief Medical Physicist at OHSU says: "OHSU is building the organization's technological platforms for advanced radiation therapy.
Johan Löf, founder and CEO, RaySearch, says: "I am greatly encouraged that OHSU will integrate RayStation with Radixact, marking another step forward in our commitment to advancing radiation technology.

Baptist Health Lexington selects RayStation

Retrieved on:

Thursday, October 26, 2023

Cyberknife, Tomotherapy, RaySearch Laboratories, Patient, Workflow, Pharmaceutical industry, Accuray, Elekta, Varian

STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- RayStation will be used to treat patients at Baptist Health Lexington as well as Baptist Health Hamburg. It will be used to plan for a wide range of delivery systems, including linear accelerators from Elekta and Varian as well as CyberKnife and Tomotherapy from Accuray. RayStation will also be used for high dose rate brachytherapy planning. The configuration includes advanced features such as fallback planning, multi-criteria optimization, dose tracking and adaptive radiation therapy.

Key Points:

RaySearch Laboratories AB (publ) announces that Baptist Health Lexington, Kentucky, USA, has begun implementation of the treatment planning system RayStation®*.
STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- RayStation will be used to treat patients at Baptist Health Lexington as well as Baptist Health Hamburg.
Chris Roty, President, Baptist Health Lexington, says: "We are pleased to be able to implement RayStation in our Baptist System.
Right now, RayStation is the only treatment planning system available that can facilitate a unified workflow for such large and diversified centers as Baptist Health Lexington and Baptist Health Hamburg and we are looking forward to a successful collaboration."

Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue

Retrieved on:

Tuesday, October 10, 2023

Conceptus, Sung, PwC, Interim, Growth, Accounting, Market for corporate control, Conceptus Inc., Patient, Management, Accuray

The Company also announced preliminary revenue for the third quarter 2023.

Key Points:

The Company also announced preliminary revenue for the third quarter 2023.
“Separately, we are very pleased with our record third quarter revenue as we continue to benefit from the focused commercial strategy that we implemented last year.
Total worldwide revenue for the third quarter of 2023 is anticipated to be approximately $17.6 million, representing growth of approximately 30% over the same quarter last year.
The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until the Company reports its full financial results for the quarter ended September 30, 2023.

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on:

Monday, October 2, 2023

The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.

Key Points:

The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.
Accuray customers are currently able to leverage real-time adaptive therapy through the company's proprietary Synchrony® technology and offline adaptive with PreciseART® radiotherapy to account for some of the anatomical changes that occur during radiation delivery.
"We're very happy to be partnering with Accuray," said Dr Karl Otto, CEO of Limbus AI.
Embedding it into the Cenos online adaptive solution will help provide for accurate and fast contouring essential to real-world clinical implementation of adaptive treatment."